A nano-cocrystal strategy to improve the dissolution rate and oral bioavailability of baicalein.
Baicalein
Bioavailability
Cocrystals
Nano-cocrystals
Journal
Asian journal of pharmaceutical sciences
ISSN: 2221-285X
Titre abrégé: Asian J Pharm Sci
Pays: Netherlands
ID NLM: 101535338
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
01
12
2017
revised:
07
03
2018
accepted:
29
04
2018
entrez:
28
2
2020
pubmed:
28
2
2020
medline:
28
2
2020
Statut:
ppublish
Résumé
Baicalein (BE) is one of the main active flavonoids representing the variety of pharmacological effects including anticancer, anti-inflammatory and cardiovascular protective activities, but it's very low solubility, dissolution rate and poor oral absorption limit the therapeutic applications. In this work, a nano-cocrystal strategy was successfully applied to improve the dissolution rate and bioavailability of BE. Baicalein-nicotinamide (BE-NCT) nano-cocrystals were prepared by high pressure homogenization and evaluated both
Identifiants
pubmed: 32104447
doi: 10.1016/j.ajps.2018.04.009
pii: S1818-0876(17)30949-2
pmc: PMC7032205
doi:
Types de publication
Journal Article
Langues
eng
Pagination
154-164Informations de copyright
© 2018 Shenyang Pharmaceutical University. Published by Elsevier B.V.
Références
Eur J Pharm Biopharm. 2014 May;87(1):107-13
pubmed: 24388913
Molecules. 2017 Jan 30;22(2):
pubmed: 28146096
Artif Cells Nanomed Biotechnol. 2013 Apr;41(2):85-91
pubmed: 23305536
Mol Pharm. 2007 May-Jun;4(3):347-54
pubmed: 17497885
J Pharm Sci. 2014 Aug;103(8):2330-7
pubmed: 24903146
Adv Drug Deliv Rev. 2007 Jul 30;59(7):631-44
pubmed: 17601629
J Control Release. 2012 Jun 28;160(3):418-30
pubmed: 22465393
Acta Crystallogr C. 2012 Jul;68(Pt 7):o262-5
pubmed: 22763693
Eur J Pharm Sci. 2017 Nov 15;109:581-586
pubmed: 28917964
Pharm Res. 2005 Jul;22(7):1050-8
pubmed: 16028005
Int J Oncol. 2005 Jan;26(1):241-6
pubmed: 15586246
Eur J Pharm Biopharm. 2012 Jan;80(1):1-3
pubmed: 21971369
Pharm Res. 2015 Jan;32(1):47-60
pubmed: 24939640
Int J Pharm. 2013 Sep 10;453(2):380-8
pubmed: 23727143
Mol Pharm. 2006 Nov-Dec;3(6):631-43
pubmed: 17140251
Eur J Pharm Biopharm. 2016 Oct;107:142-50
pubmed: 27393561
Int J Pharm. 2011 Nov 25;420(1):180-8
pubmed: 21878378
J Ethnopharmacol. 2010 Sep 15;131(2):290-9
pubmed: 20600750
Int J Pharm. 2013 Dec 15;458(1):135-40
pubmed: 24120729
Curr Drug Deliv. 2016;13(8):1358-1366
pubmed: 26953239
Arch Pharm Res. 2014 Mar;37(3):371-8
pubmed: 23771520
J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Sep 15;967:245-54
pubmed: 25129410
Int J Pharm. 2013 Oct 15;455(1-2):267-75
pubmed: 23876497
Int J Pharm. 2010 Oct 31;399(1-2):129-39
pubmed: 20674732
Int J Pharm. 2013 Aug 30;453(1):101-25
pubmed: 23207015
Pharm Res. 2010 Dec;27(12):2725-33
pubmed: 20872053
AAPS PharmSciTech. 2011 Jun;12(2):693-704
pubmed: 21598082
Acta Crystallogr C Struct Chem. 2017 Mar 1;73(Pt 3):168-175
pubmed: 28257010
Int J Pharm. 2012 Aug 20;433(1-2):157-64
pubmed: 22579996
Int J Pharm. 2011 Oct 31;419(1-2):1-11
pubmed: 21827842
Curr Drug Targets Cardiovasc Haematol Disord. 2005 Apr;5(2):177-84
pubmed: 15853750
Inflammation. 2013 Dec;36(6):1584-91
pubmed: 23892998
Int J Pharm. 2013 Aug 30;453(1):157-66
pubmed: 23751341
J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Jan 26;978-979:43-53
pubmed: 25531869
Pharm Res. 2006 Aug;23(8):1888-97
pubmed: 16832611
Eur J Pharm Biopharm. 2006 Nov;64(3):360-8
pubmed: 16846725
Drug Discov Today. 2013 Oct;18(19-20):936-49
pubmed: 23707660
J Biomed Nanotechnol. 2015 Mar;11(3):469-77
pubmed: 26307829
Eur J Pharm Sci. 2013 Sep 27;50(1):17-28
pubmed: 23567466
Biol Pharm Bull. 2009 Dec;32(12):2079-82
pubmed: 19952434
J Pharm Pharmacol. 2016 Aug;68(8):989-98
pubmed: 27283755
Int J Nanomedicine. 2008;3(3):295-309
pubmed: 18990939
Nanotechnology. 2016 Sep 30;27(39):395601
pubmed: 27535365